Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chuncheon Sacred Heart Hospital
• Treatments: Proton Pump Inhibitors

Criteria

Inclusion Criteria:

Male or Female with 18 years or more of age without history of H. pylori eradication AND

1. Patients with H. pylori associated peptic ulcer in scar stage, OR

2. Non-ulcer dyspepsia patients with H. pylori infection

Exclusion Criteria:

1. Under 18 years, OR

2. Patients with a history of previous treatment of H. pylori infection, OR

3. Pregnant or Breast feeding women, OR

4. Patients with severe renal, liver, or heart disease, OR

5. Patients with gastric malignancy, OR

6. Patients with a history of drug allergy or hypersensitivity, OR

7. Patients who had received treatment with antibiotics or proton pump inhibitors, H2 Blocker, Bismuth preparation, Anticoagulant, Ketoconazole, Glucocorticoid during the 2 weeks preceding endoscopy